Impact of endothelin-1 Lys198Asn polymorphism on coronary artery disease and endorgan damage in hypertensives

Coronary Artery Disease

Volumn 19, Issue 7, 2008, Pages 429-434

  Popov, Aron Frederik ^a   Schulz, Egbert Godehard ^b   Hinz, Jose ^a   Schmitto, Jan Dieter ^a   Seipelt, Ralf ^a   Koziolek, Michael Johann ^a   Rosenberger, Albert ^a   Schoendube, Friedrich Albert ^a   Müller, Gerhard Anton ^a  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Center of Nephrology and Dialysis Bovenden   (Germany)

Author keywords

Endothelin 1; Genetics; Hypertension; Polymorphism

Indexed keywords

ENDOTHELIN 1;

ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; DNA POLYMORPHISM; DNA SEQUENCE; FEMALE; GENE FUNCTION; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOSITY; HUMAN; HYPERTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MULTIPLE ORGAN FAILURE; PREVALENCE; PRIORITY JOURNAL; VASCULAR DISEASE;

ADULT; AGED; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; ENDOTHELIN-1; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HEART FAILURE; HOMOZYGOTE; HUMANS; HYPERTENSION; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 55749090811     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32830936e5     Document Type: Article

References (33)

1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332:411-415.
2. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, Goto K, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci U S A 1989; 86:2863-2867.
3. Yanagisawa M. The endothelin system. A new target for therapeutic intervention. Circulation 1994; 89:1320-1322.
4. Schiffrin EL, Thibault G. Plasma endothelin in human essential hypertension. Am J Hypertens 1991; 4 (4 Pt 1):303-308.
5. Luscher TF, Yang ZH, Diederich D, Buhler FR. Endothelium-derived vasoactive substances: potential role in hypertension, atherosclerosis, and vascular occlusion. J Cardiovasc Pharmacol 1989; 14 (Suppl 6):63-69.
6. Tanaka C, Kamide K, Takiuchi S, Kawano Y, Miyata T. Evaluation of the Lys198Asn and -134delA genetic polymorphisms of the endothelin-1 gene. Hypertens Res 2004; 27:367-371.
7. Vanhoutte PM. Is endothelin involved in the pathogenesis of hypertension? Hypertension 1993; 21 (6 Pt 1):747-751.
8. Kohno M, Yasunari K, Murakawa K, Yokokawa K, Horio T, Fukui T, et al. Plasma immunoreactive endothelin in essential hypertension. Am J Med 1990; 88:614-618.
9. Minami S, Yamano S, Yamamoto Y, Sasaki R, Nakashima T, Takaoka M, et al. Associations of plasma endothelin concentration with carotid atherosclerosis and asymptomatic cerebrovascular lesions in patients with essential hypertension. Hypertens Res 2001; 24:663-670.
10. Cullen JP, Bell D, Kelso EJ, McDermott BJ. Use of A-192621 to provide evidence for involvement of endothelin ET(B)-receptors in endothelin-1-mediated cardiomyocyte hypertrophy. Eur J Pharmacol 2001; 417:157-168.
11. Ruiz-Torres MP, López-Ongil S, Griera M, Díez- Marqués ML, Rodríguez-Puyol M, Rodríguez-Puyol D. The accumulation of extracellular matrix in the kidney: consequences on cellular function. J Nephrol 2005; 18:334-340.
12. Ohta K, Hirata Y, Shichiri M, Kanno K, Emori T, Tomita K, et al. Urinary excretion of endothelin-1 in normal subjects and patients with renal disease. Kidney Int 1991; 39:307-311.
13. Hocher B, Thöne-Reineke C, Rohmeiss P, Schmager F, Slowinski T, Burst V, et al. Endothelin-1 transgenic mice develop glomerulosclerosis, interstitial fibrosis, and renal cysts but not hypertension. J Clin Invest 1997; 99: 1380-1389.
14. Schulz A, Litfin A, Kossmehl P, Kreutz R. Genetic dissection of increased urinary albumin excretion in the munich wistar frömter rat. J Am Soc Nephrol 2002; 13:2706-2714.
15. Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMurray JJ, et al. The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 1999; 33:1169-1174.
16. Asai T, Ohkubo T, Katsuya T, Higaki J, Fu Y, Fukuda M, et al. Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. Hypertension 2001; 38:1321-1324.
17. Jin JJ, Nakura J, Wu Z, Yamamoto M, Abe M, Tabara Y, et al. Association of endothelin-1 gene variant with hypertension. Hypertension 2003; 41:163-167.
18. Iglarz M, Benessiano J, Philip I, Vuillaumier-Barrot S, Lasocki S, Hvass U, et al. Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 2002; 39:209-213.
19. Barden AE, Herbison CE, Beilin U, Michael CA, Wallers BN, Van Bockxmeer FM. Association between the endothelin-1 gene Lys198Asn polymorphism blood pressure and plasma endothelin-1 levels in normal and pre-eclamptic pregnancy. J Hypertens 2001; 19:1775-1782.
20. Lenfant C, Chobanian AV, Jones DW, Roccella EJ. Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Seventh report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7): resetting the hypertension sails. Hypertension 2003; 41:1178-1179.
21. Benigni A, Perico N, Remuzzi G. Research on renal endothelin in proteinunc nephropathies dictates novel strategies to prevent progression. Curr Opin Nephrol Hypertens 2001; 10:1-6.
22. Murer L, Zacchello G, Basso G, Scarpa A, Montini G, Chiozza ML, et al. Immunohistochemical distribution of endothelin in biopsies of pediatric nephrotic syndrome. Am J Nephrol 1994; 14:157-161.
23. Pinto-Sietsma SJ, Hermann SM, Schmidt-Petersen K, Niu T, Hillege HL, Janssen WM, et al. Role of the endothelin-1 gene locus for renal impairment in the general nondiabetic population. J Am Soc Nephrol 2003; 14:2596-2602.
24. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89:1573-1579.
25. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugtshita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384:353-355.
26. Zolk O, Quattek J, Sitzler G, Schrader T, Nickenig G, Schnabel P, et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999; 99:2118-2123.
27. Love MP, Ferro CJ, Haynes WG, Plumpton C, Davenport AP, Webb DJ, et al. Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc Res 2000; 47:166-172.
28. Colombo MG, Ciofini E, Paradossi U, Bevilacqua S, Biagini A. ET-I Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure. A case-control study. Cardiology 2006; 105:246-252.
29. Lerman A, Edwards BS, Hallett JW, Heubtein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactiviry in advanced atherosclerosis. N Engl J Med 1991; 325:997-1001.
30. Zeiher AM, Goebel H, Schächinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivrty of the culprit lesion in unstable angina. Circulation 1995; 91:941-947.
31. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1998; 95:14367-14372.
32. Böhm F, Ahlborg G, Johansson BL, Hansson LO, Pemow J. Combined endothelin receptor blockade evokes enhanced vasodilatation in patients with atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22:674-679.
33. Bühler K, Ufer M, Müller-Marbach A, Brinkmann U, Laute M, Stangl V, et al. Risk of coronary artery disease as influenced by variants of the human endothelin and endothelin-converting enzyme genes. Pharmacogenet Genomics 2007; 17:77-83.